Oncoral phase 1 results to be presented at ESMO congress in Munich

2018-09-10
Download
Ascelia Pharma announces today that results of the Phase I study for Oncoral has been accepted as a poster presentation at the European Society for Medical Oncology (ESMO) Annual Congress in Munich, Germany, 19-23 October 2018.

About the Phase I study:

Oncoral has been evaluated in an investigator sponsored Phase I trial at the Department of Oncology at Herlev Hospital in Denmark. The study was a dose-escalating safety, tolerability and pharmacokinetics study of orally administered Oncoral in adult patients with advanced solid tumours. The objectives of the study were to determine the safety, tolerability and maximum tolerated dose of Oncoral given as single agent and when administered in combination with the oral chemotherapeutic drug capecitabine. Additional objectives were to determine any objective tumour response or stable disease, and to describe the pharmacokinetics of Oncoral given as single agent. A total of 25 patients were enrolled in the part of the study with Oncoral given as single agent.

The results of the combination study with capecitabine will be presented at a later stage.

For further information contact:
Magnus Corfitzen, CEO, +46 735 179 110

About Ascelia Pharma

Ascelia Pharma is a specialty pharmaceutical company dedicated to the development of novel medicines to improve the life expectancy and quality of life for people living with cancer. The company is located at Medeon Science Park in Malmö, Sweden in the middle of Medicon Valley, a leading European life science cluster. For more information, please visit www.ascelia.com 

2021-10-19

Ascelia Pharma’s Food Effect Study with Orviglance successfully completed

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the last patient visit has been completed in the study to evaluate the effect of food intake on the absorption of Orviglance (Mangoral). This Food Effect Study is part of the ongoing pivotal clinical program for Orviglance and will be included in the marketing authorization package to the health authorities including FDA and EMA.
2021-09-21

Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®

Ascelia Pharma AB (publ) (ticker: ACE) today announced that it has signed a clinical collaboration agreement with Taiho Oncology Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. The collaboration concerns an upcoming global Phase 2 clinical study in gastric cancer. In this all-oral combination study, Ascelia Pharma’s irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated in combination with Taiho Oncology’s LONSURF® (trifluri ...
2021-08-19

Quarterly Report Q2 2021: Preparing Oncoral for the next level

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q2 2021 (April – June 2021), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations/